Matches in Wikidata for { <http://www.wikidata.org/entity/Q107974388> ?p ?o ?g. }
Showing items 1 to 41 of
41
with 100 items per page.
- Q107974388 description "clinical trial" @default.
- Q107974388 description "ensayo clínico" @default.
- Q107974388 description "ensayu clínicu" @default.
- Q107974388 description "klinisch onderzoek" @default.
- Q107974388 description "клінічне випробування" @default.
- Q107974388 description "临床试验" @default.
- Q107974388 name "A Phase II Study of Carelizumab Combined With Irinotecan and Apatinib of Second-line Treatment for Advanced Gastric Cancer" @default.
- Q107974388 name "A Phase II Study of Carelizumab Combined With Irinotecan and Apatinib of Second-line Treatment for Advanced Gastric Cancer" @default.
- Q107974388 type Item @default.
- Q107974388 label "A Phase II Study of Carelizumab Combined With Irinotecan and Apatinib of Second-line Treatment for Advanced Gastric Cancer" @default.
- Q107974388 label "A Phase II Study of Carelizumab Combined With Irinotecan and Apatinib of Second-line Treatment for Advanced Gastric Cancer" @default.
- Q107974388 prefLabel "A Phase II Study of Carelizumab Combined With Irinotecan and Apatinib of Second-line Treatment for Advanced Gastric Cancer" @default.
- Q107974388 prefLabel "A Phase II Study of Carelizumab Combined With Irinotecan and Apatinib of Second-line Treatment for Advanced Gastric Cancer" @default.
- Q107974388 P1132 Q107974388-B5ABBDE4-ECE0-4A43-ABA8-7512F7BF09F3 @default.
- Q107974388 P1476 Q107974388-743B956D-815D-4D01-8003-F07CCE48DD28 @default.
- Q107974388 P2899 Q107974388-D323FD6F-FBB4-41DF-AB33-92EABA7DD70E @default.
- Q107974388 P3098 Q107974388-319FAE85-DD34-453B-9E34-64446C8DF5A6 @default.
- Q107974388 P31 Q107974388-880523A7-546F-4428-83F8-6139B9202BFE @default.
- Q107974388 P4135 Q107974388-5AC70262-9870-46D5-A4AD-8DF2E8729B36 @default.
- Q107974388 P4844 Q107974388-A2874AA1-4FE3-4F68-948D-B46906B1798A @default.
- Q107974388 P4844 Q107974388-B175A574-8689-4D1B-877D-92BF27397F74 @default.
- Q107974388 P580 Q107974388-52057467-C527-4C94-BBB2-353C578E7453 @default.
- Q107974388 P582 Q107974388-BF57CBB6-C7C5-4013-871D-7C87C7F04315 @default.
- Q107974388 P6099 Q107974388-C4546C89-5361-4F57-A174-68C2758FE882 @default.
- Q107974388 P6153 Q107974388-64E1995C-DF70-489A-9D93-032F6BF059AE @default.
- Q107974388 P8005 Q107974388-98C91482-8331-44DC-BFA8-31EF273958C5 @default.
- Q107974388 P8363 Q107974388-4C6B9FDA-1ACC-493F-B224-7A23C761F16B @default.
- Q107974388 P1132 "+85" @default.
- Q107974388 P1476 "A Single-arm, Multicenter, Open-labeled, Phase II Study on the Efficacy and Safety of Carelizumab Combined With Irinotecan and Apatinib in the Second-line Treatment of Locally Advanced Unresectable, Recurrent or Metastatic Adenocarcinoma of Stomach and Gastroesophageal Junction" @default.
- Q107974388 P2899 "+18" @default.
- Q107974388 P3098 "NCT04934618" @default.
- Q107974388 P31 Q30612 @default.
- Q107974388 P4135 "+75" @default.
- Q107974388 P4844 Q27262801 @default.
- Q107974388 P4844 Q412197 @default.
- Q107974388 P580 "2020-05-19T00:00:00Z" @default.
- Q107974388 P582 "2023-05-19T00:00:00Z" @default.
- Q107974388 P6099 Q42824440 @default.
- Q107974388 P6153 Q10907979 @default.
- Q107974388 P8005 Q76649708 @default.
- Q107974388 P8363 Q78089383 @default.